This paper described modifications to the design of an open-label study to characterize asthma exacerbations in patients treated with benralizumab, in order to safely obtain clinical, physiological, and airway inflammation data during the COVID-19 pandemic. One modification to the study design will be to move from on-site spirometry at all visits to on-site spirometry at selected visits plus home spirometry using the Vitalograph Micro spirometer with video supervision.
- Author Smith S et al.
- Publication European Respiratory Journal
- Year 2021
- Device Type Micro
